The von Hippel-Lindau tumor suppressor gene expression level has prognostic value in neuroblastoma

International Journal of Cancer

Volumn 119, Issue 3, 2006, Pages 624-629

  Hoebeeck, Jasmien ^a   Vandesompele, Jo ^a   Nilsson, Helén ^b   De Preter, Katleen ^a   Van Roy, Nadine ^a   De Smet, Els ^a   Yigit, Nurten ^a   De Paepe, Anne ^a   Laureys, Geneviève ^a   Påhlman, Sven ^b   Speleman, Frank ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LUND UNIVERSITY   (Sweden)

Author keywords

3p deletion; Hypoxia; Neuroblastoma; Survival; VHL (von Hippel Lindau)

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; OXYGEN; PROTEIN TYROSINE KINASE A; TUMOR MARKER; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL DIFFERENTIATION; CELL HYPOXIA; CHROMAFFIN CELL; CHROMOSOME 11Q; CHROMOSOME 3; CHROMOSOME DELETION; FAMILIAL CANCER; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NEURAL CREST CELL; NEUROBLAST; NEUROBLASTOMA; NEWBORN; ONCOGENE MYC; OXYGEN SENSING; PHENOTYPE; PHEOCHROMOCYTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN STABILITY; RISK ASSESSMENT; SCHOOL CHILD; TUMOR SUPPRESSOR GENE; VHL GENE;

BLOTTING, WESTERN; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFANT; INFANT, NEWBORN; MUTATION; NEUROBLASTOMA; PROGNOSIS; RNA, MESSENGER; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33745494694     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21888     Document Type: Article

References (28)

1. Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, Combaret V, Favrot MC, Delattre O, Michon J, Benaid J, Hartmann O, Nicholson JC, et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 2001;91:680-6.
2. Luttikhuis ME, Powell JE, Rees SA, Genus T, Chughtai S, Ramani P, Mann JR, McConville CM. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis. Br J Cancer 2001;85:531-7.
3. Vandesompele J, Van Roy N, Van Gele M, Laureys G, Ambros P, Heimann P, Devalck C, Schuuring E, Brock P, Otten J, Gyselinck J, De Paepe A, et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer 1998;23:141-52.
4. Guo C, White PS, Hogarty MD, Brodeur GM, Gerbing R, Stram DO, Maris JM. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. Med Pediatr Oncol 2000;35:544-6.
5. Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinskchmidt C, Christiansen H, Lampert F, Lastowska M, Bown N, Pearson A, Nicholson JC, Ross F, et al. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? Med Pediatr Oncol 2001;36:5-10.
6. Ejeskar K, Aburatani H, Abrahamsson J, Kogner P, Martinsson T. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br J Cancer 1998;77:1787-91.
7. Hallstensson K, Thulin S, Aburatani H, Hippo Y, Martinsson T. Representational difference analysis and loss of heterozygosity studies detect 3p deletions in neuroblastoma. Eur J Cancer 1997;33:1966-70.
8. Mosse YP, Greshock J, Margolin A, Naylor T, Cole K, Khazi D, Hii G, Winter C, Shahzad S, Asziz MU, Biegel JA, Weber BL, et al. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 2005;43:390-403.
9. Maher ER, Kaelin WG, Jr. von Hippel-Lindau disease. Medicine (Baltimore) 1997;76:381-91.
10. Kessler PM, Vasavada SP, Rackley RR, Stackhouse T, Duh FM, Latif F, Lerman MI, Zbar B, Williams BR. Expression of the von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol Med 1995;1:457-66.
11. Los M, Jansen GH, Kaelin WG, Lips CJ, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 1996;75:231-8.
12. Nagashima Y, Miyagi Y, Udagawa K, Taki A, Misugi K, Sakai N, Kondo K, Kaneko S, Yao M, Shuin T. von Hippel-Lindau tumour suppressor gene. Localization of expression by in situ hybridization. J Pathol 1996;180:271-4.
13. Richards FM, Schofield PN, Fleming S, Maher ER. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 1996;5:639-44.
14. Kanno H, Saljooque F, Yamamoto I, Hattori S, Yao M, Shuin T, U HS. Role of the von Hippel-Lindau tumor suppressor protein during neuronal differentiation. Cancer Res 2000;60:2820-4.
15. Murata H, Tajima N, Nagashima Y, Yao M, Baba M, Goto M, Kawamoto S, Yamamoto I, Okuda K, Kanno H. von Hippel-Lindau tumor suppressor protein transforms human neuroblastoma cells into functional neuron-like cells. Cancer Res 2002;62:7004-11.
16. Van Roy N, Van Limbergen H, Vandesompele J, Van Gele M, Poppe B, Salwen H, Laureys G, Manoel N, De Paepe A, Speleman F. Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines. Genes Chromosomes Cancer 2001;32:126-35.
17. Nilsson H, Jogi A, Beckman S, Harris AL, Poellinger L, Pahlman S. HIF-2α expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Exp Cell Res 2005;303:447-56.
18. Vandesompele J, De Paepe A, Speleman F. Elimination of primer-dimer artifacts and genomic coamplification using a two-step SYBR green I real-time RT-PCR. Anal Biochem 2002;303:95-8.
19. Pattyn F, Speleman F, De Paepe A, Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res 2003;31:122-3.
20. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
21. Hoebeeck J, van der Luijt R, Poppe B, De Smet E, Yigit N, Claes K, Zewald R, de Jong GJ, De Paepe A, Speleman F, Vandesompele J. Rapid detection of VHL exon deletions using real-time quantitative PCR. Lab Invest 2005;85:24-33.
22. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
23. Van Roy N, Laureys G, Cheng NC, Willem P, Opdenakker G, Versteeg R, Speleman F. 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer 1994;10:103-14.
24. Waye JS, Willard HF. Chromosome specificity of satellite DNAs: short- and long-range organization of a diverged dimeric subset of human α satellite from chromosome 3. Chromosoma 1989;97:475-80.
25. Rothberg PG, Bradley JF, Baker DW, Huelsman KM. Is the P25L a "real" VHL mutation? Mol Diagn 2001;6:49-54.
26. Jogi A, Ora I, Nilsson H, Lindeheim A, Makino Y, Poellinger L, Axelson H, Pahlman S. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 2002;99:7021-6.
27. Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M, Kartal A, Flynn D, Wiedemeyer R, Schwab M, Schafer H, Christiansen H, et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2002;2:377-86.
28. Zeidman R, Lofgren B, Pahlman S, Larsson C. PKCepsilon, via its regulatory domain and independently of its catalytic domain, induces neurite-like processes in neuroblastoma cells. J Cell Biol 1999;145:713-26.